Stacey Seltzer is a Partner at Gurnet Point Capital, joining in 2022. Prior to joining GPC, Stacey was a Partner at Aisling Capital where she invested in life sciences companies. Over the course of her 14 years at Aisling, Stacey’s board service included Agile Therapeutics, Aimmune Therapeutics (acquired by Nestle Health), AVROBIO, Durata Therapeutics (acquired by Actavis), Miramar Labs (acquired by Sientra), Promentis Pharmaceuticals, Prolacta Bioscience, Spruce Biosciences and ZELTIQ Aesthetics (acquired by Allergan). Prior to Aisling, Stacey was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the US Schering-Plough Brand Lead for Zetia.

Prior to Schering-Plough, Stacey was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Stacey began her career as a management consultant for McKinsey & Company. Stacey also currently serves as a director of Reneo Pharmaceuticals on the Yale School of Management Advisory Board, the Life Science Council for Springboard Enterprises and the Investment Advisory Board of the Blavatnik Fund for Innovation at Yale. Stacey received her M.B.A. from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar. She received her M.S. and B.S. from Yale University, awarded cum laude in Molecular Biophysics and Biochemistry.